Cargando…
Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms
BACKGROUND: The use of methotrexate is limited by interindividual variability in response. Previous studies in patients with either rheumatoid arthritis or psoriasis suggest that genetic variation across the methotrexate metabolic pathway might enable prediction of both efficacy and toxicity of the...
Autores principales: | Warren, RB, Smith, RL, Campalani, E, Eyre, S, Smith, CH, Barker, JNWN, Worthington, J, Griffiths, CEM |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680291/ https://www.ncbi.nlm.nih.gov/pubmed/19016697 http://dx.doi.org/10.1111/j.1365-2133.2008.08898.x |
Ejemplares similares
-
Polymorphisms in the PTPN22 region are associated with psoriasis of early onset
por: Smith, RhLl, et al.
Publicado: (2008) -
A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real‐world populations in psoriasis
por: Yiu, Z.Z.N., et al.
Publicado: (2019) -
Genetic susceptibility to psoriasis: an emerging picture
por: Smith, Rhodri Ll, et al.
Publicado: (2009) -
Psoriasis treat to target: defining outcomes in psoriasis using data from a real‐world, population‐based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR)
por: Mahil, S.K., et al.
Publicado: (2019) -
Comparative effectiveness of biological therapies on improvements in quality of life in patients with psoriasis
por: Iskandar, I.Y.K., et al.
Publicado: (2017)